StreetAlpha.app
Home › Stocks › ABBV

AbbVie Inc. (ABBV)

Healthcare
$292.78
▼ −0.60%
LAST CLOSE · NOV 17

AbbVie develops and sells prescription medicines for immunology, neuroscience and oncology, including Skyrizi and Rinvoq. It last closed at $292.78 on Nov 17, down 0.60% on the day. ABBV reports earnings on Wed, Feb 3, 2027. The average 12-month price target from 14 analysts is $321.79 (+9.9% from the last close), with a high of $346.00 and a low of $294.00. Analyst consensus is Strong Buy, based on the latest ratings from 14 firms (12 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 5 whale options trades in ABBV, 20% of them bullish and 80% bearish. In the past 30 days there were 28 dark pool prints totaling $28.6M, the largest $2.4M.

AI Auto Pilots
Is ABBV in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$66.0B
+10.7% vs a year ago
Net income
$10.3B
+333.1% vs a year ago
EPS (diluted)
$5.81
+340.2% vs a year ago
Free cash flow
$18.9B
28.6% margin
Valuation
Market cap
$518B
1.77B shares
P/E
50.4
Price over 12 month EPS
Price to sales
7.8
Market cap over revenue
Dividend yield
2.36%
$6.92 a share over 12 months
Balance sheet
Cash & equivalents
$10.8B
At Sep 30
Shareholder equity
−$4.6B
Buybacks
$1.5B
Last 12 months
CEORobert A. Michael
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $56.2B$56.2BFY2021FY2022: $58.1B$58.1BFY2022FY2023: $54.3B$54.3BFY2023FY2024: $56.3B$56.3BFY2024FY2025: $61.2B$61.2BFY2025

From ABBV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 3
2027 · Time not announced
Consensus EPS forecast
$3.89
$18.34B revenue est.
Year-ago EPS
$2.71
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 14 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
14firms
12 Buy2 Hold0 Sell
Each firm's latest rating on ABBV in the past 90 days
Average 12-month target
$321.79
▲ 9.9% upside

Based on 14 analysts who set a price target on ABBV in the past 90 days. The average target is $321.79, with a high of $346.00 and a low of $294.00, compared with the last close of $292.78.

$202$254$305$357PAST 111 TRADING DAYS12-MONTH TARGETSHIGH $346AVG $321.79LOW $294May 22LAST CLOSE+12 MO$202$254$305$357PAST 111 DAYSTARGETSHIGH $346AVG $321.79LOW $294May 22LAST CLOSE+12 MO
Highest target$346.00
Average target$321.79
Lowest target$294.00
Latest rating changes
BarclaysTarget raised
Nov 16Buy$325 → $335
UBSTarget raised
Nov 2Hold$275 → $295
Leerink PartnersMaintained
Nov 2Buy$342
Morgan StanleyTarget raised
Nov 2Buy$310 → $346
GuggenheimTarget raised
Nov 2Buy$288 → $322
DateFirmActionRatingPrice target
Nov 16BarclaysTarget raisedBuy$325 → $335
Nov 2UBSTarget raisedHold$275 → $295
Nov 2Leerink PartnersMaintainedBuy$342
Nov 2Morgan StanleyTarget raisedBuy$310 → $346
Nov 2GuggenheimTarget raisedBuy$288 → $322
Loading…

Technical Analysis

ABBV · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 5% above its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 59). The nearest support is the Pivot at $292.61, and the nearest resistance the Pivot R1 at $294.23.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.3%/day
Key levels
$302.9352 week high+3.5%
$298.74Swing high (Oct 30)+2.0%
$294.23Pivot R1+0.5%
$292.78Last close
$292.61Pivot−0.1%
$291.17Pivot S1−0.5%
$290.4320 day average−0.8%
$281.23Swing low (Oct 28)−3.9%
$277.1550 day average−5.3%
$265.77100 day average−9.2%
$241.48200 day average−17.5%
$190.7552 week low−34.8%
Indicators
RSI (14)58.63Middle of its rangeNeutral
MACD4.79Below its signal lineBearish
Stochastic59.7Middle of its rangeNeutral
ADX (14)29.8Trending up
Williams %R-46.4Oversold below −80, overbought above −20Neutral
CCI (20)42.8Oversold below −100, overbought above 100Neutral
Rate of change+2.4%Change over 10 sessionsBullish
ATR (14)$6.66Typical daily range, 2.3% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for ABBV

What happened before

See how ABBV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish1 bullish and 4 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow ABBV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ABBV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
5
Bullish
1
20%
Bearish
4
80%
Date span
Oct 7 – Nov 5
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
28
Notional
$28.6M
Largest print
$2.4M
Loading…

ABBV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●1,908 buying vs 1,731 selling
  • ▼Held by funds -2.1 pts
  • ●Funds holding +20
  • ▼Superinvestors: 0 added, 4 cut
  • ▲Put/call 1.38 to 1.14
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4,2604,240+0.5%
In funds' top 10200199+0.5%
Held by funds74.1%76.2%−2.1 pts
New / increased169 / 1,739229 / 1,868−9.0%
Reduced / sold out1,632 / 991,512 / 112+6.6%
Put/call ratio1.141.38−17.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABBV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ABBV Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.5B
0.3% yield
Left in program
$1.8B
0.4% of value
Shares outstanding, 12 months
+0.0%
More shares
Last quarter
$600K
Sep 2026
Avg price paid, last quarter
$249.74
2K shares bought
S&P 500 rank by spending
#134 of 358
 
Spent each quarter, last 3 yearsTop bar $1.1B
Dec 2023: $4.3M, average price $152.39Mar 2024: $959.9M, average price $180.44Jun 2024: $522K, average price $167.04Sep 2024: $495K, average price $181.35Dec 2024: $352.9M, average price $173.84Mar 2025: $606.4M, average price $213.63Jun 2025: $596K, average price $187.52Sep 2025: $600K, average price $198.16Dec 2025: $5.9M, average price $224.36Mar 2026: $1.1B, average price $230.40Jun 2026: $625K, average price $209.81Sep 2026: $600K, average price $249.74
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Nov 3, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABBV is in one of them and how their past ABBV trades turned out.

ABBV in the AI portfolios
Loading…

ABBV News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABBV in an article yet. Here's the latest on the wider market.

ABBV Congress Trades

All congress trades →
Trades, 12 months
31
Buys
15
48%
Sells
14
45%
People
9
Last filed Nov 5
Who traded ABBV · since 2014
Latest 5 filings of 227
$15K – $50KTraded Oct 7, 2026Filed Nov 5, 2026
$15K – $50KTraded Sep 4, 2026Filed Oct 7, 2026
$50K – $100KTraded Jul 31, 2026Filed Sep 22, 2026
$50K – $100KTraded Jul 23, 2026Filed Sep 22, 2026
$15K – $50KTraded Sep 14, 2026Filed Sep 21, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CABuy$15K – $50KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CASell$15K – $50KSep 4, 2026Oct 7, 202633 d
Donald J TrumpExecutive branchBuy$50K – $100KJul 31, 2026Sep 22, 202653 d
Donald J TrumpExecutive branchBuy$50K – $100KJul 23, 2026Sep 22, 202661 d
Pete SessionsR · TXSell$15K – $50KSep 14, 2026Sep 21, 20267 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About AbbVie

AbbVie is a biopharmaceutical company based in North Chicago, Illinois. It researches, develops, manufactures and sells prescription medicines in immunology, neuroscience and oncology, including Skyrizi, Rinvoq and Botox Therapeutic. Its treatments are used by patients with autoimmune diseases, migraine, Parkinson's disease and several blood cancers. The company sells its products in many countries around the world.

Headquarters
North Chicago, IL
Founded
2012